Exane Derivatives Adaptimmune Therapeutics PLC Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Exane Derivatives holds 121 shares of ADAP stock, worth $61. This represents 0.0% of its overall portfolio holdings.
Number of Shares
121
Previous 121
-0.0%
Holding current value
$61
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ADAP
# of Institutions
83Shares Held
123MCall Options Held
34.2KPut Options Held
16.3K-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$14 Million0.69% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR20.5MShares$10.5 Million0.38% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$8.71 Million0.66% of portfolio
-
Two Seas Capital LP Rye, NY14.8MShares$7.57 Million1.31% of portfolio
-
Baillie Gifford & CO11.8MShares$6.03 Million0.01% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $83.3M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...